Us Bancorp \De\ Harmony Biosciences Holdings, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 575 shares of HRMY stock, worth $19,958. This represents 0.0% of its overall portfolio holdings.

Number of Shares

575

Previous 10,099 94.31%

Holding current value

$19,958

Previous $304,000 92.76%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$30.0 - $39.95 $285,720 - $380,483	-9,524 Reduced 94.31%	575 $22,000
Q2 2024 Aug 06, 2024	BUY	$28.81 - $33.01 $58,772 - $67,340	2,040 Added 25.31%	10,099 $304,000
Q1 2024 May 07, 2024	SELL	$29.93 - $35.06 $17,389 - $20,369	-581 Reduced 6.72%	8,059 $270,000
Q4 2023 Feb 09, 2024	BUY	$19.2 - $33.78 $147,321 - $259,193	7,673 Added 793.49%	8,640 $279,000
Q3 2023 Nov 03, 2023	SELL	$31.89 - $39.03 $56,094 - $68,653	-1,759 Reduced 64.53%	967 $31,000
Q2 2023 Aug 09, 2023	BUY	$30.5 - $37.4 $14,182 - $17,391	465 Added 20.57%	2,726 $95,000
Q1 2023 May 09, 2023	BUY	$30.8 - $53.92 $13,921 - $24,371	452 Added 24.99%	2,261 $73,000
Q4 2022 Feb 13, 2023	BUY	$45.4 - $60.91 $52,210 - $70,046	1,150 Added 174.51%	1,809 $99,000
Q3 2022 Oct 27, 2022	BUY	$42.06 - $55.45 $26,708 - $35,210	635 Added 2645.83%	659 $29,000
Q2 2022 Aug 01, 2022	SELL	$33.54 - $52.15 $3,186 - $4,954	-95 Reduced 79.83%	24 $1,000
Q1 2022 May 11, 2022	BUY	$33.14 - $51.13 $3,943 - $6,084	119 New	119 $6,000
Q3 2021 Nov 10, 2021	SELL	$25.68 - $38.61 $436 - $656	-17 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$25.96 - $33.44 $441 - $568	17 New	17 $0

Others Institutions Holding HRMY

# of Institutions

243

Shares Held

45.2M

Call Options Held

108K

Put Options Held

49.2K

View Full List

About Harmony Biosciences Holdings, Inc.

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.05B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

More about HRMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account